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Oral Cytokine Levels Are More Linked to Levels of Plasma 
and Oral HIV-1 RNA Than to CD4+ T-Cell Counts in 
People With HIV
Joseph M. Rocco,1,  Zachary York,2 Chengli Shen,1 Caroline Shiboski,3 Jennifer Cyriaque-Webster,4 Janet McLaughlin,1 Luann Borowski,1 Huichao Chen,5 
Judith A. Aberg,6 Dirk P. Dittmer,4 Mahmoud Ghannoum,7 Charles R. Rinaldo,1 and Bernard Macatangay1
1University of Pittsburgh, Pittsburgh, Pennsylvania, USA, 2University of Wisconsin-Madison, Madison, Wisconsin, USA, 3University of California San Francisco, San Francisco, California, USA, 
4University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA, 5Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA, 6Icahn School of Medicine at Mount Sinai, 
New York, New York, USA, and 7Case Western Reserve University, Cleveland, Ohio, USA
Background. We determined the levels of 11 soluble immune mediators in oral washings of AIDS Clinical Trials Group A5254 
participants with varying degrees of plasma viremia and CD4 T-cell counts to characterize the mucosal immune response at different 
stages of HIV-1 infection.
Methods. A5254 was a multicenter, cross-sectional study in people with HIV (PWH) recruited into 4 strata based on CD4 count 
and levels of plasma viremia: stratum (St) A: CD4 ≤200 cells/mm3, HIV-1 RNA (viral load [VL]) >1000 cps/mL; St B: CD4 ≤200, VL 
≤1000; St C: CD4 >200, VL >1000; St D: CD4 >200, VL ≤1000. Oral/throat washings were obtained from all participants. Soluble 
markers were tested in oral/throat washings using a multibead fluorescent platform and were compared across strata. Linear regres-
sion was used to determine the associations between cytokines and HIV-1 in plasma and oral fluid.
Results. St A participants had higher levels of interleukin (IL)-1β, IL-6, IL-17, tumor necrosis factor alpha (TNFα), and inter-
feron gamma (IFNγ) compared with St B and D (P = .02; P < .0001) but were not different from St C. IL-8, IL-10, and IL-12 were 
elevated in St A compared with the other 3 strata (P = .046; P < .0001). Linear regression demonstrated that oral HIV-1 levels were 
associated with IL-1β, IL-6, IL-8, and TNFα production (R > .40; P <  .001) when controlling for CD4 count and opportunistic 
infections.
Conclusions. Our results show that high levels of oral HIV-1, rather than low CD4 counts, were linked to the production of oral 
immune mediators. Participants with AIDS and uncontrolled viremia demonstrated higher levels of pro- and anti-inflammatory sol-
uble immune mediators compared with participants with lower HIV-1 RNA. The interplay of HIV-1 and these immune mediators 
could be important in the oral health of PWH. 
Keywords.  HIV-1; cytokines; humans; immune response; saliva.
HIV-1 infection disrupts oral mucosal immunity, but the 
pathogenesis of this immune dysregulation remains unclear. 
Progressive HIV-1 infection and subsequent immune defi-
ciency increase susceptibility to a variety of oral opportunistic 
infections (OIs) including oral candidiasis, hairy leukoplakia, 
and Kaposi’s sarcoma [1]. In healthy individuals, oral mucosal 
immunity is maintained by a combination of cellular and mo-
lecular components [2]. Epithelial cells maintain the mucosal 
barrier, express pattern recognition receptors, and secrete 
cytokines and host defense peptides in response to pathogenic 
stimuli [2]. A variety of immune cells also aid in the mainte-
nance of mucosal immunity and the oral microbiome [3].
During HIV-1 infection, the saliva is known to harbor viral 
particles, cytokines, and anti-HIV-1 antibodies [4]. HIV-1 infec-
tion is believed to cause significant oral immune dysregulation 
by altering local cytokine expression, leading to alterations in 
local innate immunity and, subsequently, a poor immune re-
sponse to infectious exposures [2]. Multiple variables have been 
shown to impact the oral production of soluble immune medi-
ators during HIV-1 infection, including ART use, CD4 T-cell 
count, HIV-1 viral load (VL), smoking status, opportunistic 
infections, and time from HIV-1 diagnosis [5–11]. However, 
the relative contribution of these factors to the oral cytokine re-
sponse remains undefined.
We aimed to formally assess the effects of HIV-1 viremia 
and CD4 T cells on oral immunity using oral/throat wash 
samples, plasma HIV-1 VL, CD4 T-cell counts, and demo-
graphic data obtained through the AIDS Clinical Trials Group 
(ACTG) A5254 protocol. This cross-sectional study evaluated 
whether nonprofessional oral health specialists could accurately 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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diagnose common oral lesions in this population [12]. A  fol-
low-up study by Dittmer et al. [13] using this same study pop-
ulation showed increased detection rates of cytomegalovirus 
(CMV) and herpes simplex–1 virus (HSV-1), but not Epstein-
Barr virus (EBV) or human herpesvirus 8 (HHV8 aka Kaposi’s 
sarcoma–associated herpesvirus) in the oral cavity of those with 
AIDS and an HIV-1 VL >1000 copies/mL [13]. Only oral CMV 
shedding was directly associated with plasma HIV-1 VL when 
controlling for other variables [13].
 In the present study, using the previously obtained clinical 
data and cryopreserved oral/throat wash specimens from ACTG 
A5254 [12], we determined the association between levels of 
plasma and oral HIV-1 RNA and CD4 T-cell count on the ex-
pression of the oral soluble mediators interleukin (IL)-1β, IL-2, 
IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, interferon gamma 
(IFNγ), and tumor necrosis factor alpha (TNFα). To provide 
a comprehensive evaluation, we measured both pro- and an-
ti-inflammatory cytokines that are associated with innate im-
munity and different T-helper cell responses (Th1, Th2, Th17) 
so we could better characterize the effects of these variables on 
local mucosal immunity. We also evaluated the impact of oral 
co-infection with Candida, CMV, EBV, HSV-1, and HHV-8 on 
soluble mediator levels.
METHODS
Study Design
ACTG A5254 is a multicenter cross-sectional study that en-
rolled PWH aged 18 years or older with or without prior use of 
ART across 5 clinical sites in the United States and 1 in Haiti. 
Participants had plasma HIV-1 RNA VL and CD4 T-cell counts 
obtained during enrollment. Those receiving ART needed to be 
on the same regimen for at least 12 weeks before enrollment. 
Participants not taking ART must have stopped all ART for at 
least 30 days before study entry. OI prophylaxis was not included 
in the inclusion criteria, but use of systemic antifungal therapy 
within 90 days of enrollment was an exclusion criterion. The in-
stitutional review board or ethics committee of each participating 
institution approved the study, and each patient gave written in-
formed consent. Detailed information on study design and popu-
lation characteristics has been previously published [12].
Participants were divided into 4 strata according to their 
screening CD4 T-cell count and HIV-1 RNA VL regardless of 
whether they were on ART (Table 1).
Stratum A: CD4 ≤200 cells/mm3, plasma HIV-1 VL >1000 
copies/mL
Stratum B: CD4 ≤200 cells/mm3, plasma HIV-1 VL ≤1000 
copies/mL
Stratum C: CD4 >200 cells/mm3, plasma HIV-1 VL >1000 
copies/mL
Stratum D: CD4 >200 cells/mm3, plasma HIV-1 VL ≤1000 
copies/mL
A 1-minute oral/throat wash using 10 mL of sterile saline was 
collected and frozen in aliquots at –80°C. Oral/throat wash 
samples were used to measure oral HIV-1 RNA and soluble im-
mune mediators. CD4 counts and levels of HIV-1 RNA in both 
plasma and oral fluid were measured in Clinical Laboratory 
Improvement Amendments (CLIA)-certified laboratories at 
the individual ACTG-participating clinical lab sites in A5254.
Evaluation of Oral Soluble Immune Mediators, Coinfections, and OIs
Cryopreserved oral/throat wash specimens were thawed, 
and oral cytokine concentrations of IL-1β, IL-2, IL-4, IL-6, 
IL-8, IL-10, IL-12, IL-13, IL-17, IFNγ, and TNFα were ana-
lyzed using an electrochemiluminescence platform (Meso 
Scale Discovery, Rockville, MD, USA). Real-time quantita-
tive polymerase chain reaction was used to detect multiple 
herpesviruses (CMV, EBV, KSHV, HSV-1), as described 
previously [13]. Oral examination was also performed for 
OIs (eg, candidiasis, hairy leukoplakia) by an Oral Health 
Specialist at each participating ACTG clinical site. In all 
participants, 2.5  mL of the oral/throat wash specimen was 
extracted and cultured for the presence of Candida as previ-
ously  described [12].
Statistical Analysis
Cytokine differences between each stratum were evaluated 
using the Kruskal-Wallis test with the Dunn’s post-test adjusted 
for multiple comparisons to accommodate the non-normal dis-
tribution of the data. GraphPad Prism statistical analysis soft-
ware was used to perform these analyses and generate figures. 
Linear regression analysis was used to model the relationship 
between cytokine production and oral or plasma HIV VL while 
controlling for CD4 count, oral candidiasis, and human her-
pesviruses. The VL and cytokines were log-transformed for 
this analysis. P values <.05 and R values ≥.40 were considered 
significant.
RESULTS
Sample Characteristics
Of the 328 participants who were enrolled in A5254, 288 
participants with available specimens and oral HIV-1 RNA 
were included in this analysis (Table  1). The median age 
was 44 years, with a female:male ratio of ~2:1. The partici-
pants predominately identified as black, non-Latino (72%), 
and reported no history of intravenous drug use (85%). The 
majority of participants were receiving ART (67%) at study 
entry, and only 8% reported a history of an AIDS-defining 
illness. Fewer participants were enrolled in strata C and D 
(CD4  >200), as the aim of the initial study was to recruit 
those at higher risk of oral OIs. The overall number of HIV-
1-related oral OIs was high among all participants, with rates 
of oral candidiasis at 47%, hairy leukoplakia at 12%, and 
Kaposi’s sarcoma at 10%.
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Differences in Oral Production of Immune Mediators Among the Strata
The pro-inflammatory immune mediators TNFα, IL-1β, 
IL-6, and IL-8 were significantly higher in stratum A  com-
pared with stratum B or stratum D (P < .001) (Figure 1A–D). 
Strata A  and B consisted of participants with CD4  ≤200 and 
were only differentiated by a plasma HIV-1 RNA >1000 copies/
mL in stratum A and ≤1000 copies/mL in stratum B.  In con-
trast, stratum D includes only those study participants with 
CD4 >200 and plasma HIV-1 RNA ≤1000 copies/mL. IL-8 pro-
duction was also significantly increased in stratum A compared 
Table 1. Study Participant Demographics
 N = 288 A (n = 148) B (n = 82) C (n = 29) D (n = 29)
Age, median, y 44 41 47 38 45
Sex, No. (%)      
 Male 193 (67) 83 (56) 70 (85) 20 (69) 22 (75)
 Female 95 (33) 65 (44) 12 (15) 9 (31) 7 (25)
Race, No. (%)      
 Black, non-Latino 207 (72) 132 (89) 48 (59) 18 (62) 12 (42)
 White, non-Latino 49 (17) 7 (5) 6 (7) 7 (24) 5 (17)
 Latino 26 (9) 6 (4) 26 (32) 4 (14) 11 (38)
 other 6 (2) 3 (2) 2 (2) 0 (0) 1 (3)
Intravenous drug use, No. (%)      
 Never used 245 (85) 133 (90) 63 (77) 24 (83) 23 (79)
 Current use 3 (1) 2 (1) 1 (1) 0 (0) 1 (3)
 Past use 40 (14) 13 (9) 18 (22) 5 (17) 5 (18)
Currently on ART, No. (%) 193 (67) 77 (52) 80 (98) 6 (21) 29 (100)
History of an AIDS-defining illness, No. (%) 23 (8) 7 (5) 10 (12) 3 (10) 2 (7)
Abbreviation: ART, antiretroviral therapy.
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Figure 1. Differences in oral production of tumor necrosis factor alpha (TNFα), interleukin (IL)-1β, IL-6, and IL-8 between the strata.
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with stratum C (P = .045), which both had viremia of >1000 but 
were differentiated by a CD4 ≤200 in stratum A and CD4 >200 
in stratum C. Despite differences in CD4 counts, no differences 
were observed between Strata B and D, both of which had vi-
remia <1000 cps/mL.
There were increased levels of both IL-12 and IFNγ in stratum 
A compared with stratum B (both P < .001) or stratum D (P = .03 
and P < .001, respectively) (Figure 2A, B). Similarly, IL-12 pro-
duction was higher in stratum A  compared with stratum C 
(P  =  .002). IFNγ was the only cytokine with higher levels in 
stratum B and stratum C compared with stratum D (P =  .004 
and P  =  .039, respectively) (Figure  2B). IL-17, an important 
cytokine in maintaining gut mucosal immunity [14], was also 
elevated in stratum A compared with stratum B (P =  .004) or 
stratum D (P =  .021) (Figure 2C). Meanwhile, levels of IL-10, 
an anti-inflammatory cytokine, were significantly increased in 
stratum A  when compared with the other 3 strata (P  <  .001) 
(Figure 2D). There were no substantial differences noted among 
the strata in levels of IL-2, IL-4, or IL-13 (data not shown).
Relationship Between Plasma HIV-1 VL and Oral Immune Mediator 
Production
The differences in soluble markers among the strata suggest that 
HIV-1 viremia influences cytokine dysregulation more than 
differences in CD4 T-cell counts. We therefore used linear re-
gression modeling to evaluate the relationship between plasma 
HIV-1 VL and oral immune mediator levels while controlling 
for CD4 T-cell counts, oral candidiasis, and human herpes-
virus shedding. The strongest associations were observed be-
tween plasma HIV-1 RNA and TNFα (R = .53), IL-1β (R = .38), 
IL-6 (R  =  .42), and IL-8 (R  =  .42), all with P values <.001 
(Figure 3A–D). No significant associations were found between 
plasma HIV-1 VL and IL-12, IFNγ, IL-17, IL-10, IL-4, IL-13, or 
IL-2 (data not shown).
Relationship Between Oral HIV-1 VL and Oral Cytokine Production
As oral HIV-1 RNA strongly correlated with plasma HIV-1 
viremia (R  =  .76; P  <  .001), we determined whether levels of 
HIV-1 in oral fluid are also associated with levels of the im-
mune mediators. The strongest associations were noted be-
tween oral HIV-1 VL and the production of TNFα (R =  .60), 
IL-1β (R =  .45), IL-6 (R =  .46), and IL-8 (R =  .52) when con-
trolling for CD4 T-cell count, OIs, and co-infections (all P < 
.001) (Figure  3E–H). Although associations were similar, the 
correlations of soluble immune mediator levels with oral HIV-1 
RNA were greater than with plasma HIV-1 RNA. No significant 
associations were identified between oral HIV-1 VL and IL-12, 
IFNγ, IL-17, IL-10, IL-4, IL-13, or IL-2 (data not shown).
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Figure 2. Differences in oral production of interferon gamma, interleukin (IL)-12p70, IL-10, and IL-17 between the strata.
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Relationship Between CD4 T-Cell Count, Coinfections and OIs, and Oral 
Cytokine Production
Additional linear regression analyses were performed to eval-
uate associations between CD4 T-cell counts and oral cytokine 
production while controlling for HIV-1 VL, coinfections, and 
OIs. No associations were identified among these 3 param-
eters. We also evaluated if OIs (oral candidiasis) and human 
herpesvirus shedding (CMV, EBV, HHV-8, HSV-1) were sig-
nificantly impacting production of specific cytokines. Linear 
regressions were performed comparing each OI or coinfection 
to the individual cytokines, while controlling for HIV-1 VL and 
CD4 counts, but no specific associations were found (data not 
shown). We then performed this same analysis using only strata 
B and D, as the majority of these participants were on ART 
(98%–100%) and therefore represented a sample more perti-
nent to the current HIV treatment era. However, again no OIs 
or coinfections were found to be significantly associated with 
any specific cytokine production in this population (data not 
shown).
DISCUSSION
We provide a comprehensive evaluation of the pathogenic ef-
fects of plasma and oral HIV-1 VL on oral mucosal cytokine 
production at different CD4 T-cell counts. We evaluated the oral 
mucosal production of 11 different soluble immune mediators 
as well as oral HIV-1 VL, oral candidiasis, and 4 human her-
pesviruses (CMV, EBV, HSV-1, HHV-8). In participants with 
poorly controlled HIV-1 infection (stratum A: CD4  ≤200, 
HIV-1 VL >1000), there was a significant increase in the oral 
production of the majority of cytokines tested, including IL-1β, 
IL-6, IL-8, IL-10, IL-12, IL-17, IFNγ, and TNFα. These cyto-
kines are associated with both pro- and anti-inflammatory im-
mune responses, and many of them correspond to different 
CD4 T-helper cell responses, including Th1 (IL-12, IFNγ), Th2 
(IL-10), and Th17 (IL-17) [2, 15].
This aberrant increase of both pro- and anti-inflammatory 
cytokines appears counterintuitive but likely reflects the se-
vere degree of mucosal immune dysregulation in this patient 
population. IL-10, an anti-inflammatory cytokine, serves as a 
critical regulator of inflammation, and its production is stimu-
lated by many of the same pattern recognition receptors (PRRs) 
that drive early pro-inflammatory immune responses [16]. 
This dysregulated oral cytokine production provides a poten-
tial mechanistic explanation for the high risk of oral OIs and 
coinfections in this group.
Differences among the strata suggest that HIV-1 VL is a sig-
nificant factor in driving this aberrant cytokine production. 
This was evidenced by the dramatic decrease in cytokine levels 
from stratum A to stratum B. Participants in these strata all had 
CD4 counts ≤200; however, those in stratum B were essentially 
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all (ie, 98%) on “effective” ART with controlled plasma viremia 
<1000 cps/mL. This significant decrease in cytokine production 
between stratum A  and stratum B was seen in all cytokines, 
which were elevated in stratum A  (IL-1β, IL-6, IL-8, IL-10, 
IL-12, IL-17, IFNγ, TNFα). A  similar decrease in production 
was seen in each of these cytokines between stratum A  and 
stratum D.  All participants in stratum D were also well con-
trolled on ART, with plasma viremia <1000 cps/mL and CD4 
counts >200.
Our comparisons of oral cytokine levels, CD4 T-cell counts, 
and both oral and blood HIV-1 VL during “effective” ART are 
of particular importance. A  recent cross-sectional study by 
Elizondo et  al. [10] compared gingival crevicular fluid cyto-
kine production based on duration of ART (non-ART, ART-
naïve [ART <1 year], short-term ART [>1 year and <6 years], 
and long-term ART [>6 years]) and found increased IL-6, IL-7, 
IL-10, and IL-12 in the gingival crevicular fluid of the non-ART 
group compared with the others. In contrast to our results, they 
did not find differences in other pro-inflammatory cytokines 
(IL-1β, IL-8, IL-17, TNFα, IFNγ) among these groups [10]. 
They concluded that HIV-1 viremia and ART are important 
factors in oral cytokine expression.
Lomeli-Martinez et  al. [11] showed that participants with 
lower CD4 counts (CD4 ≤200) not on ART had higher levels 
of IFNγ, IL-10, IL-6, and IL-4 compared with those with CD4 
counts >200 on ART. They also described increased oral pro-
duction of TNFα, IFNγ, IL-10, and IL-4 in participants with 
CD4 counts ≤200 compared with those with CD4 >200, even 
when both groups were on ART. There were differences in 
HIV-1 plasma VL between these groups, but they did not eval-
uate for associations between plasma viremia and oral cyto-
kine production. Similar cross-sectional studies by Nittayanta 
et al. [6, 7] compared production of oral immune mediators 
among PWH grouped based on duration of ART. In contrast 
to the prior studies, they showed increased production of IL-8 
and human β-defensin in participants on short- and long-
term ART compared with no ART; however, they reported 
no differences in TNFα or IL-6 production [6, 7]. They also 
found no difference in cytokine production in individuals 
with plasma HIV-1 VL <50 cps/mL compared with those with 
HIV-1 VL ≥50 cps/mL.
These previous studies combined with our results highlight 
the complex involvement of multiple variables in the produc-
tion of oral immune mediators; however, ART and HIV-1 VL 
appear to be crucial in this process. Other variables such as 
Candida and herpesvirus infections have also consistently been 
shown to affect oral mucosal immunity [3, 8, 11]. Therefore, 
to more effectively evaluate the association between oral and 
plasma HIV-1 VL in terms of individual cytokine production, 
we performed linear regression analysis to control for key vari-
ables such as CD4 count, OIs (candidiasis), and herpesvirus 
infections (CMV, EBV, HSV-1, HHV-8). Linear regression 
identified TNFα, IL-1β, IL-6, and IL-8 as having the strongest 
associations with both oral and plasma HIV-1 VL using an R 
value >.40 as significant. IL-10, IL-12, IL-17, and IFNγ all had 
much weaker associations with HIV-1 VL, with R values around 
.10. Spear et al. performed a similar study in 2005 and found 
no significant associations between saliva HIV-1 RNA and oral 
cytokine production (IL-1β, IFN-γ, IL-10, IL-6, TNF-α) [9]. 
However, they did not perform a linear regression analysis and 
were not able to control for potential confounders. They also 
had a smaller sample size and detected saliva HIV-1 RNA in 
only 20 participants, potentially explaining the discrepancy be-
tween our results.
Interactions within the cytokine network are complex, but 
TNFα, IL-1β, IL-6, and IL-8 share common features that could 
explain their strong association with HIV-1 viremia in our 
study. They are relatively nonspecific, pro-inflammatory cyto-
kines that are released early in the innate immune response 
[17]. They are secreted by immune cells, along with epithelial 
cells, keratinocytes, and fibroblasts [17]. Thus, we hypothesize 
that a high viral burden in the oral mucosa would persistently 
stimulate local PRRs on epithelial and immune cells, driving the 
production of these early pro-inflammatory mediators.
A notable limitation of our study is that 52% of the partici-
pants in stratum A were reportedly taking ART but had HIV-1 
VLs >1000. Although this is a confounder for our results in 
stratum A, it is important to note that strata B and D provide a 
more accurate representation of participants on “effective” ART, 
with >98% on ART, and control of HIV-1 viremia (<1000 cps/
mL). The earlier described studies demonstrate conflicting re-
sults on ART use and changes in mucosal cytokine production 
[6, 7, 10, 11]. Our results describe pertinent differences in oral 
immune mediators between participants with uncontrolled vi-
remia on or off ART (stratum A) compared with those taking 
ART with effectively controlled HIV-1 virus replication (strata 
B and D). Based on these findings and the linear regression re-
sults, plasma and oral HIV-1 VL impact production of immune 
mediators. Future studies should consider not only ART status 
but control of plasma and oral HIV-1 VL when evaluating oral 
mucosal immunity.
Additionally, the improvements in mucosal cytokine produc-
tion between stratum A and stratum B are supported by clinical 
observations described in the initial paper by Shiboski et al. [12]. 
The prevalence of oral candidiasis was 71% in stratum A com-
pared with only 22% in stratum B, which was similar to the com-
bined prevalence of oral candidiasis in strata C and D (22%) [12]. 
Oral candidiasis often resolves rapidly with the initiation of ART; 
this may be explained by the rapid resolution in aberrant cyto-
kine production demonstrated between stratum A and stratum 
B.  Both CMV and HSV-1 oral shedding were significantly de-
creased in stratum B compared with stratum A, indicating that 
improvement in cytokine dysregulation could assist in immune-
mediated suppression of herpesvirus reactivations [13].
Oral Cytokine Levels in HIV-1 Infection • ofid • 7
Other notable limitations of our study include the small 
sample sizes in strata C and D.  The primary objective of the 
original study was to evaluate the prevalence of oral OIs, and 
therefore a higher number of individuals with CD4 counts ≤200 
were enrolled in strata A and B. Detailed evaluation of perio-
dontal health was not objectively graded in our study, and we 
were unable to evaluate the effect of periodontal disease on oral 
cytokine expression. Due to the cross-sectional design, clin-
ical data were available from only 1 visit, and only oral/throat 
wash samples were collected as part of the research protocol. 
Additionally, per the original research protocol, a cutoff of 
plasma HIV-1 VL >1000 cps/mL was chosen to delineate the 
strata, rather than viral suppression by commercial assays, 
which could limit the generalizability of the results. Finally, a 
large number of participants in stratum A were enrolled in Haiti 
compared with the participants in the other strata, who were 
largely enrolled from US domestic sites; this represents a poten-
tial confounder.
HIV-1 is associated with compromised oral mucosal im-
munity [1]. Our study demonstrates severe oral immune 
dysregulation in participants with poorly controlled viremia 
and low CD4 counts, which likely contributes to the increased 
prevalence of oral OIs and coinfection with herpesviruses in 
this population. This oral immune dysfunction is directly as-
sociated with the amount of HIV-1 virus present both locally 
and systemically, although multiple other variables including 
CD4 count, OIs, and herpesvirus coinfections are also involved. 
There was a notable improvement in oral cytokine dysregulation 
with ART use and suppression of HIV-1 viremia, leading to 
clinical restoration of mucosal immunity. These improvements 
decreased the risk of oral candidiasis and reduced the shed-
ding of human herpesviruses. However, it is well established 
that systemic immunity does not return to a baseline level with 
HIV-1 viral suppression or normalization of the CD4 count [3]. 
Subtle immune deficits persist in the oral mucosa, as evidenced 
by higher rates of periodontal disease and HPV oral infections, 
even in those with controlled HIV-1 infection on ART [18, 19]. 
Future studies on the mechanisms of chronic inflammation and 
their impact on the oral microbiome in well-controlled HIV-1 
infection are essential.
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